ketorolac / Generic mfg. - LARVOL DELTA

Drugs for acute treatment of migraine. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • CNS Disorders • Migraine • Pain

Discovering repurposable drugs for Alzheimer's disease and related dementias: target trial emulation using decentralised real-world data. (PubMed, EBioMedicine) - "20 widely used medications may be associated with reduced progression from MCI to ADRD and represent promising candidates for clinical evaluation as repurposed therapies for dementia."

Journal • Real-world evidence • Alzheimer's Disease • Cardiovascular • CNS Disorders • Cognitive Disorders • Dementia • Pain

Unexpected Reaction to RSV Vaccine in a Patient with Known Ketorolac Trometamol Allergy: A Case Highlighting the Importance of Excipient Awareness (EADV 2026) - No abstract available

Clinical • Allergy • Immunology • Respiratory Syncytial Virus Infections

Determination of 33 non-steroidal anti-inflammatory drug residues in horse urine by QuEChERS-ultra performance liquid chromatography-tandem mass spectrometry (PubMed, Se Pu) - "The results revealed the presence of three NSAIDs， including ketorolac， lornoxicam and naproxen， with contents ranging from < LOQ to 6.87 μg/L. Lornoxicam is a banned substance and is strictly prohibited for use in horses at any time. The proposed method is simple， efficient and accurate， and is suitable for the simultaneous determination of the 33 NSAIDs residues in horse urine samples."

Journal • Inflammation • Pain

Safety of short-term non-steroidal anti-inflammatory drug use in the postoperative setting in paediatric patients with chronic kidney disease: protocol for a randomised, placebo-controlled trial. (PubMed, BMJ Open) - P4 | "Patients aged >18 months will be randomised 1:1 to receive ketorolac/ibuprofen or placebo for ≤5 days postoperatively...Secondary outcomes are postoperative pain scores and opioid use (reported as morphine equivalents/kg/day)...Study findings will be disseminated through presentation at scientific meetings and publications in peer-reviewed journals. NCT06860711."

Clinical protocol • Journal • Acute Kidney Injury • Chronic Kidney Disease • Nephrology • Pain • Pediatrics • Renal Disease • Urology

Biased μ-opioid receptor agonist tegileridine for postoperative analgesia after gynecologic laparoscopy or abdominal surgery: a prospective, double-blind, randomized controlled trial (ChiCTR) - P=N/A | N=124 | Not yet recruiting | Sponsor: Maternal and Child Health Hospital of Jiangxi Province; Maternal and Child Health Hospital of Jiangxi Province

New trial

Cancer Cachexia Research and Drug Development: Lessons from Failures and the Promise of Immunomodulation. (PubMed, Cancers (Basel)) - "Particular emphasis is given to novel immunomodulatory strategies, including agents such as R-ketorolac, which may restore immune homeostasis and target the root causes of cachexia. It is hypothesized that future therapeutic success will likely depend on integrated approaches combining immunological, metabolic, nutritional, and rehabilitative interventions."

Journal • Review • Cachexia • Immunology • Metabolic Disorders • Oncology

Non-Biologic Injections in Sports Medicine. (PubMed, Curr Rev Musculoskelet Med) - "Accordingly, treatment selection requires careful consideration of the underlying pathology, therapeutic goals, safety profile, and available evidence. This review synthesizes the current literature to provide clinicians with a practical, evidence-based framework for the use of non-biologic injections in sports medicine."

Journal • Review • Anesthesia • Immunology • Musculoskeletal Diseases • Osteoarthritis • Pain • Rheumatology

Opioid-Sparing Effect of Suzetrigine in Total Knee Arthroplasty and Knee Arthroplasty Revision (PAINWeek 2026) - "Generalizability of results is limited by surgeries studied (ie, abdominoplasty and bunionectomy), an inconsistent efficacy benefit compared with hydrocodone-acetaminophen, and a uncertain impact on opioid use...Outcomes evaluated included postoperative opioid prescribing at discharge and prior to the 2-week follow-up appointment (quantified by Morphine Equivalent Daily Dose [MEDD] and total Morphine Milligram Equivalents [MME]), pain control and functional recovery (assessed via pre- and postoperative knee Range of Motion [ROM], Knee injury and Osteoarthritis Outcome Score for Joint Replacement [KOOS JR], and Patient-Reported Outcomes Measurement Information System [PROMIS] scores)...The perioperative standard of care was consistent across the evaluation period; this included an intraoperative “joint cocktail” (bupivacaine, ketorolac, epinephrine +/- clonidine) and a postoperative multimodal regimen of scheduled acetaminophen and NSAID unless contraindicated, in..."

Addiction (Opioid and Alcohol) • CNS Disorders • NAV1

Comparison of Discharge Readiness Between Propofol-Dexmedetomidine versus Propofol-Ketorolac for Ambulatory Dilation and Curettage: A Randomized Controlled Trial (PAINWeek 2026) - "Patients receiving dexmedetomidine required significantly lower total propofol doses compared with the ketorolac group (102.4 ± SD mg vs 106.6 ± SD mg; p=0.02). A higher proportion of patients in the dexmedetomidine group achieved MPADSS ≥9 within 30 minutes compared with the ketorolac group (66.7% vs 40% , p=0.04 ). Postoperative hypotension (23.3% vs 46.7% , p=0.06 ), nausea (46.7% vs 66.7% , p=0.12 ), vomiting (26.7% vs 63.3% , p=0.001 ), and pain complaints (20% vs 36.6%, p=0.15) were less frequent in the dexmedetomidine group."

Clinical • CNS Disorders

Balancing Pain Control and Safety: Association of Peri-operative Ketorolac Use in Pediatric Testicular and Penile Surgeries and Post-operative Outcomes (MA-AUA 2026) - No abstract available

Clinical • Surgery • Pain • Pediatrics

Atomized Intranasal Ketorolac at 30 mg Versus 20 mg for the Treatment of Acute Pain in the Emergency Department: A Randomized Non-inferiority Trial (clinicaltrials.gov) - P3 | N=100 | Not yet recruiting | Sponsor: Tehran University of Medical Sciences

Head-to-Head • New P3 trial • Pain

Oral Ketorolac for IUD Pain Reduction (clinicaltrials.gov) - P2 | N=108 | Enrolling by invitation | Sponsor: University of North Carolina, Chapel Hill | Trial completion date: Jun 2026 ➔ Aug 2027 | Trial primary completion date: Jun 2026 ➔ Aug 2027

Trial completion date • Trial primary completion date • Long-acting Reversible Contraceptives • Pain

The effect of low-dose ketorolac on minimally invasive transforaminal lumbar interbody fusions: final analysis of a randomized, double-blinded, placebo-controlled trial. (PubMed, J Neurosurg Spine) - P4 | "Short-term, low-dose ketorolac following MIS TLIF with BMP maintained noninferior fusion rates while providing significant reductions in opioid requirements, hospital stay, and early postoperative pain. Clinical trial registration no.: NCT03278691 (ClinicalTrials.gov)."

Clinical • Journal • Addiction (Opioid and Alcohol) • Pain

Post-Crosslinked Hydrazidine-Functionalized Resorcinol-Formaldehyde Imprinted Polymer for Selective S-Ketorolac Recognition. (PubMed, Chirality) - "The Langmuir model fits better than the Freundlich model, pointing to adsorption on defined binding sites. With a selectivity coefficient of about 12, it shows effective stereoselective recognition, making S-KR-P a great option for separating chiral ketorolac."

Journal

Comparison of enhanced recovery after surgery protocol and standard protocol for cesarean delivery: A two-center, double-blind, randomized controlled trial. (PubMed, Int J Surg) - "The ERAC bundle included: preoperative personalized and information-based education; intraoperative prophylactic phenylephrine infusion, mandatory non-opioid analgesia (intravenous acetaminophen and ketorolac), prophylaxis for postoperative nausea and vomiting (ondansetron/dexamethasone), and active fluid warming; and postoperative scheduled ketorolac. No significant differences were found in pain at rest, length of stay, or anxiety scores. An anesthesiologist-led, bundled ERAC protocol significantly reduced perioperative adverse events and enhanced the quality of recovery after elective cesarean delivery compared to conventional care."

Journal • Anesthesia • Dermatology • Hypotension • Pain • Pruritus • Psychiatry

Postoperative Pain After Pediatric Adenotonsillectomy With Ketorolac or Ibuprofen (clinicaltrials.gov) - P=N/A | N=200 | Recruiting | Sponsor: Baylor College of Medicine | Not yet recruiting ➔ Recruiting | Trial completion date: Jun 2027 ➔ Jun 2028

Enrollment open • Trial completion date • Pain • Pediatrics

Subcutaneous Administration of Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) for Pain Management: A Systematic Review and Meta-Analysis. (PubMed, J Pain Palliat Care Pharmacother) - "Four RCTs (n = 825) were included: three placebo-controlled trials and one route-comparison trial, all evaluating short-term treatment for acute pain with subcutaneous diclofenac or ketorolac...However, the evidence is limited and safety remains uncertain. Further route-comparison studies are needed."

Journal • Review • Pain

PACESS: Post-cesarean Analgesia: Comparing Effectiveness of Staggered v. Simultaneous Therapies (clinicaltrials.gov) - P4 | N=825 | Active, not recruiting | Sponsor: Thomas Jefferson University | Recruiting ➔ Active, not recruiting | Trial primary completion date: Aug 2027 ➔ Jul 2026

Enrollment closed • Trial primary completion date • Pain

Study on Ketorolac for Improving Outcomes and Prognosis in Patients With Stanford Type A Aortic Dissection (clinicaltrials.gov) - P3 | N=1346 | Recruiting | Sponsor: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | N=360 ➔ 1346 | Trial completion date: Sep 2028 ➔ Dec 2028

Enrollment change • Trial completion date • Inflammation

Catastrophic Gastric Hemorrhage and Necrosis After Short Course-Scheduled NSAID Therapy Despite Ulcer Prophylaxis (ACG 2026) - "For fracture-related pain, he was managed with a multimodal analgesic regimen that included scheduled ketorolac 15 mg every 6 hours for 3 days, along with concurrent ulcer prophylaxis...Figure: Endoscopic views of the stomach showing retained blood products and a large necrotic-appearing fundal ulcer with adherent clot and focal active oozing. Figure: Gross partial gastrectomy specimen showing extensive hemorrhagic gastric necrotic tissue."

Acute Kidney Injury • Cardiovascular • Chronic Kidney Disease • Congestive Heart Failure • Coronary Artery Disease • Gastroenterology • Heart Failure • Hematological Disorders • Hypotension • Musculoskeletal Diseases • Nephrology • Orthopedics • Peptic Ulcer

Off the Beaten Limb: Remnant Duodenitis as a Rare Cause of Recurrent Melena After Roux-en-Y Gastric Bypass (ACG 2026) - "He reported development of melenic stool following an episode of heavy drinking after a period of sobriety, while also endorsing newly initiating âTawon Liarâ, an Indonesian supplement consisting of meloxicam, ketorolac, dexamethasone, and tramadol, among other herbal ingredients. Figure: Figure 1. View of pylorus and remnant stomach from retrograde approach (1a, 1b); broader view of remnant stomach (1c), partially circumferential duodenitis displayed on retrograde approach through afferent limb (1d)."

Bariatric surgery • Fibrosis • Gastroenterology • Gastroesophageal Reflux Disease • Genetic Disorders • Hepatology • Immunology • Obesity • Peptic Ulcer

Association between postoperative ketorolac use and pseudarthrosis following anterior lumbar interbody fusion: retrospective analysis of a multicenter national database. (PubMed, J Neurosurg Spine) - "Ketorolac is a safe adjunct to pain control following ALIF. Administration was not found to be associated with increased pseudarthrosis or reoperation rates at the 2-year follow-up. There were no significant differences in acute postoperative events at 90 days postoperatively. Further studies are warranted to evaluate the effect of postoperative NSAIDs on outcomes in anterior lumbar fusion surgery."

Journal • Retrospective data • Infectious Disease • Osteoarthritis • Pain

Comparison of common pharmacological strategies for post-photorefractive keratectomy pain management: a systematic review and network meta-analysis. (PubMed, Front Med (Lausanne)) - "Regarding safety, Diclofenac (SUCRA = 0.81), Ketorolac (0.70), and Nepafenac (0.53) demonstrated the optimal profiles. The highest numbers of adverse events occurred with Pregabalin (39 cases), Fentanyl (20 cases), and Codeine combined with Acetaminophen (13 cases); however, safety conclusions remain limited as only seven studies reported highly heterogeneous adverse event data...Clinicians should synthesize these comparative findings with individual patient profiles to optimize drug selection, ensuring a balanced approach between effective pain relief and minimized adverse risks. https://www.crd.york.ac.uk/PROSPERO/view/CRD420251238092, CRD420251238092."

Journal • Retrospective data • Review • Pain

The Effect of Intra-Canal Ketorolac Application on Post-Endodontic Pain (clinicaltrials.gov) - P1 | N=45 | Completed | Sponsor: Al-Azhar University | Recruiting ➔ Completed | Trial completion date: Oct 2025 ➔ Feb 2026 | Trial primary completion date: Sep 2025 ➔ Feb 2026

Trial completion • Trial completion date • Trial primary completion date • Pain